Vectra DA test changes treatment decisions, and may improve functional status and reduce costs.

“Over the 10 year time horizon, quality-adjusted life years increased by 0.08 years and costs decreased by US$457 (cost savings in disability-related medical costs, US$659; in productivity costs, US$2137).”

Michaud K, et al. Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. Rheumatology (Oxford). 2015 Sep; 54(9): 1640–9.

Learn More View Article